Overcoming Barriers to Equitable Care in HNSCC

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Immune Checkpoint Therapy for Patients With Recurrent or Metastatic HNSCC

Overcoming Barriers to Equitable Care in HNSCC

ReachMD Healthcare Image
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
  • Overview

    In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Nabil Saba, MD, FACP
    Vice Chair, Hematology and Medical Oncology
    Emory University Hospital
    Atlanta, GA

    Dr. Saba has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Adagene, Astex, AstraZeneca, Aveo, BioNTech, BMS, Celldex, Coherus, Cornerstone, CUE, Eisai Medical, EMD Serono, Exelixis, Faron Pharmaceutical, Flamingo, Fulgent, GSK, Imugene, Infinity, Inovio, Kura, Medscape, Merck, Nanobiotix, OncLive, Pfizer, Seagen, Springer, Surface Oncology, Taiho, Tosk, UpToDate, Vaccinex

    Barbara Burtness, MD
    Professor of Medicine (Medical Oncology)
    Yale University
    New Haven, CT

    Dr. Burtness has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Research: Cue BioPharma, Daichi, Merck KgA, Merck
    Consulting Fees: AbbieVie, ALX Oncology, AstraZeneca, Coherus, Cue BioPharma, GlaxoSmithKiline, Janssen, Kura, Merck, Merck KgA, Mirati, Orphagen, Rakuten, Seagen, Vaccinex,
    Expert Testimony: Arnold and Porter

    Reviewers/Content Planners/Authors:

    • Jennifer Brutsche has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Bob Garris has nothing to disclose.
    • Wilma Guerra has nothing to disclose.
    • Samantha Keehn has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Patti Repetto has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate the latest evidence on the efficacy of current and emerging immunotherapy-based regimens for recurrent, unresectable, or metastatic head and neck squamous cell carcinoma (HNSCC)
    • Develop individualized treatment plans for patients with recurrent, unresectable, or metastatic HNSCC based on the latest guideline recommendations and clinical trial data 
    • Explain the role of biomarkers in predicting response to immunotherapy-based therapy regimens and detecting disease recurrence 
    • Implement recommended strategies to identify and manage adverse events in patients receiving immuno-oncology-based therapy regimens for HNSCC 
    • Recognize how social determinants of health and barriers to accessing healthcare services contribute to geographic and racial disparities in HNSCC outcomes 
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pathologists, nurses, nurse practitioners, physician assistants, and pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until May 3rd, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.50 contact hours/0.05 CEUs of pharmacy contact hours.1 

    The Universal Activity Number for this program is JA0006235-0000-24-053-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Commercial Support

    This activity is supported by an independent educational grant from Merck Sharp & Dohme LLC. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule19 Jul 2024